A study by Akiyama et al
For those on a GLP-1 journey, products like our GLP-1 Daily Support supplement can help manage common digestive hurdles and support overall metabolic health
In a randomized clinical trial, tesamorelin reduced visceral adipose tissue and liver fat in HIV-infected patients (Stanley et al., JAMA, 2014), and its Phase 3 program (Falutz et al.) established the visceral-fat effect that underpins its FDA approval
SURPASS-AP-combo, respective clinical trial registration numbers NCT04537923, NCT04255433, NCT03861052, NCT03861039, NCT04093752) are not completed yet
Head to head comparison of GLP-1 analogs The clinical results achieved by short-, long, and prolonged-acting GLP-1 analogs have now been tested across different studies and in direct head to head comparison studies